For people living with HIV, age-related comorbidities, such as obesity and diabetes, as well as quality-of-life issues remain challenges. Our Peer Exchange panel discusses clinical approaches for this patient population and trying to keep them in good health.
The federal agency is going to lay out recommendations for states.
Although COVID-19 vaccination remains the primary focus for health care, other paramount vaccines need to be recognized. Here is a review.
This is the first authorized COVID-19 vaccine that was developed by a Canadian-based company, and the first that used a plant-based protein technology.
CDC expands recommended timeline between second and third COVID-19 vaccine to 8 weeks for people 12 years and older, especially for young men, to reduce the risk of myocarditis.
The FDA approved the One Male Condom as the first condom approved and proven to protect against STIs and HIV during anal sex.
Pfizer’s TicoVac vaccine was developed to immunize young children and adults to prevent Tick-Borne Encephalitis.
The IDSA, HIVMA, and SHEA released a statement opposing legal intervention on behalf of ivermectin as a COVID-19 treatment.
The 2019 Strategic Plan of the Infectious Diseases Society of America lays the groundwork for understanding prescribing practices.
A clinician offers his perspective on how the virus is behaving and the role that vaccines and therapies will play.
Moderna was endorsed to begin phase 3 clinical trials for mRNA-1345, what could be the first respiratory syncytial virus (RSV) vaccine.
COVID-19 patients’ ZIP codes influenced how sick they were upon hospitalization, and how much care they needed after admittance.
A review of treatment modalities for this patient population.
Latest update of the bill introduced in the House November, but no word on a potential vote yet.
Shorter durations of antibiotic therapy demonstrate similar efficacy and may improve safety compared with longer courses for certain infections.
Study highlights elevated levels of antibody response in those with history of COVID-19.
COVID-19 mRNA vaccine effectiveness wanes even faster during Omicron than during Delta variant predominance, but a booster dose still provides lasting defense against COVID-19 hospitalization and death.
A study of patients at high risk of severe COVID-19 disease progression found ivermectin was no more effective than standard care at preventing adverse outcomes.
Regular symptom screening revealed completely asymptomatic COVID-19 infection is highly unlikely among unvaccinated people.
As the number of COVID-19 cases continues to rise, oral treatment options for at-home use are in demand to provide early intervention and reduce the progression to severe disease, hospitalization, and death.
The varicella zoster (chickenpox) virus has been essentially eradicated thanks to the vaccine developed by Japanese virologist Dr. Michiaki Takahashi, who would have been 94 years old today.
Investigators looked at myocardial infarction risks over several years within 2 health care systems examining both people with HIV (PWH) and people without HIV (PWoH).
Investigators examined the efficacy and safety of carbapenems vs select novel antibiotics for treatment of cUTI.
The investigational therapy has demonstrated promising results utilizing subcutaneous injections every 6 months.
Hispanic/Latino people face disproportionately high HIV incidence, but one CROI 2022 study found those not born in the US are more likely to have stage 3 HIV (AIDS) diagnoses.
Due to policies rolling out HIV pre-exposure prophylaxis (PrEP) and commencing antiretroviral therapy at diagnosis, the UK is on track to eliminate new HIV infections among gay and bisexual men in approximately 25 years.
For people living with HIV (PLWH) an accelerated aging process may affect the severity of their disease.
This nitroimidazole antibiotic is shown to be efficacious for this condition.
After presenting at CROI 2022, Dr. Jessica Justman discusses her community-level survey findings: COVID-19 infections do not vary by age.
